Wayne Hummer Investments L.L.C. Sells 10,364 Shares of Gilead Sciences, Inc. (GILD)

Wayne Hummer Investments L.L.C. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,922 shares of the biopharmaceutical company’s stock after selling 10,364 shares during the quarter. Wayne Hummer Investments L.L.C.’s holdings in Gilead Sciences were worth $804,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Welch Investments LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $108,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences during the 2nd quarter worth $147,000. Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the period. Finally, Rowland & Co. Investment Counsel ADV purchased a new position in shares of Gilead Sciences during the 2nd quarter worth $153,000. 75.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $81.74 on Thursday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The stock has a market capitalization of $106,750.00, a price-to-earnings ratio of 9.30, a P/E/G ratio of -1.71 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the prior year, the firm earned $2.75 EPS. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. Gilead Sciences’s dividend payout ratio is presently 23.66%.

GILD has been the topic of a number of recent analyst reports. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target on the stock in a research note on Friday, October 13th. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. BMO Capital Markets reduced their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Mizuho increased their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $85.53.

In other news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold 491,666 shares of company stock valued at $36,442,567 over the last 90 days. Insiders own 1.30% of the company’s stock.

WARNING: “Wayne Hummer Investments L.L.C. Sells 10,364 Shares of Gilead Sciences, Inc. (GILD)” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://stocknewstimes.com/2018/01/18/wayne-hummer-investments-l-l-c-sells-10364-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply